MedPath

Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

Completed
Conditions
Diabetes Mellitus, Type 2
Diabetes
Interventions
Registration Number
NCT01542060
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
298
Inclusion Criteria
  • Subjects from hospitals or clinics, diagnosed with type 2 diabetes mellitus
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BIAsp 30 usersbiphasic insulin aspart 30-
Primary Outcome Measures
NameTimeMethod
HbA1c (glycosylated haemoglobin)
Secondary Outcome Measures
NameTimeMethod
Incidence of adverse events
Incidence of hypoglycaemic episodes
FBG (Fasting Blood Glucose)
Quality of life assessed through the WHO-DTSQ (World Health Organization-Diabetes Treatment Satisfaction Questionnaire)
© Copyright 2025. All Rights Reserved by MedPath